Catalyst
Slingshot members are tracking this event:
Immunomedics (IMMU) to initiate Phase 3 study of IMMU-132 (sacituzumab govitecan) in triple-negative breast cancer in early 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 15, 2017
Occurred Source:
http://www.immunomedics.com/pdfs/news/2017/pr03152017.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Sacituzumab Govitecan, Immu-132, Triple Negative Breast Cancer
